Quinn M, Allen E
National Cancer Registration Bureau, Office of Population Censuses and Surveys, London.
BMJ. 1995 Nov 25;311(7017):1391-5. doi: 10.1136/bmj.311.7017.1391.
To assess the impact of the NHS breast screening programme on the incidence of and mortality from breast cancer.
Comparison of age specific incidence and mortality before and after the introduction of screening in the late 1980s.
England and Wales.
Women aged over 30 years.
In 1992 the age standardised incidence of breast cancer was 40% higher than in 1979. After the introduction of screening in 1988 recorded incidence rates rose steeply in the screened age group (50-64 year olds) but not in others. In 1992 the rates levelled off at about 25% higher than in 1987. Total mortality from breast cancer has increased steadily since the 1950s; the rates increased earlier in the younger age groups. By the mid-1980s rates had begun to fall in the younger age groups; but total mortality was still among the highest in the world. Age standardised mortality in the 55-69 age group changed little during the first three years of screening but then fell steeply and in 1994 was 12% lower than in 1987.
Since the introduction of screening there have been pronounced increases in recorded incidence in the screened age group. Cancer registries have an essential role in assessing screening programmes and cancer services. The steep decrease in mortality in 55-69 year olds which began three years after screening started is unlikely to be due to screening. The widespread adoption of treatment with tamoxifen during this period may be important. With the reduction in mortality already observed and the expected additional benefits from screening, the Health of the Nation target should be achieved.
评估英国国家医疗服务体系(NHS)乳腺筛查项目对乳腺癌发病率和死亡率的影响。
比较20世纪80年代末引入筛查前后特定年龄组的发病率和死亡率。
英格兰和威尔士。
30岁以上女性。
1992年,乳腺癌的年龄标准化发病率比1979年高40%。1988年引入筛查后,筛查年龄组(50 - 64岁)的记录发病率急剧上升,而其他年龄组则没有。1992年,发病率稳定在比1987年高约25%的水平。自20世纪50年代以来,乳腺癌的总死亡率一直在稳步上升;年轻年龄组的死亡率上升得更早。到20世纪80年代中期,年轻年龄组的死亡率开始下降;但总死亡率仍位居世界最高之列。在筛查的头三年,55 - 69岁年龄组的年龄标准化死亡率变化不大,但随后急剧下降,1994年比1987年低12%。
自引入筛查以来,筛查年龄组的记录发病率显著增加。癌症登记处对评估筛查项目和癌症服务至关重要。筛查开始三年后55 - 69岁人群死亡率的急剧下降不太可能是由于筛查。在此期间广泛采用他莫昔芬治疗可能很重要。鉴于已经观察到的死亡率下降以及筛查预期的额外益处,《国民健康》目标应该能够实现。